In addition, it was further revealed that the survival was worse and the overall relapse time was shorter in patients with positive HER-2 expression and lymph node metastasis than in patients with negative HER-2 expression and without lymph node metastasis [39]. The gene discussed is ERBB2; the disease is metastatic malignant neoplasm in the lymph nodes.